BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 27439470)

  • 21. HPV genotyping and E6/E7 transcript assays for cervical lesion detection in an Asian screening population-Cobas and Aptima HPV tests.
    Wong OGW; Tsun OKL; Tsui EY; Chow JNK; Ip PPC; Cheung ANY
    J Clin Virol; 2018 Dec; 109():13-18. PubMed ID: 30368218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Head-to-Head Comparison of DH3 HPV Test and HC2 Assay for Detection of High-Risk HPV Infection in Residual Cytology Samples from Cervical Cancer Screening Setting: Baseline and 3-Year Longitudinal Data.
    Fu Y; Li X; Li Y; Lu W; Xie X; Wang X
    Microbiol Spectr; 2022 Feb; 10(1):e0157021. PubMed ID: 35171029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection and genotyping of HPV-DNA through different types of diagnostic platforms in liquid-based cervical-cytology samples.
    Cassani B; Soldano G; Finocchiaro D; Conti S; Bulfamante A; Lemorini G; Bulfamante G
    Pathologica; 2018 Dec; 110(4):294-301. PubMed ID: 30799441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary HPV testing with cytology versus cytology alone in cervical screening-A prospective randomized controlled trial with two rounds of screening in a Chinese population.
    Chan KKL; Liu SS; Wei N; Ngu SF; Chu MMY; Tse KY; Lau LSK; Cheung ANY; Ngan HYS
    Int J Cancer; 2020 Aug; 147(4):1152-1162. PubMed ID: 31922265
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Urine collection in cervical cancer screening - analytical comparison of two HPV DNA assays.
    Tranberg M; Jensen JS; Bech BH; Andersen B
    BMC Infect Dis; 2020 Dec; 20(1):926. PubMed ID: 33276740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program.
    Lazcano-Ponce E; Lörincz AT; Salmerón J; Fernández I; Cruz A; Hernández P; Mejia I; Hernández-Avila M
    Cancer Causes Control; 2010 Oct; 21(10):1693-700. PubMed ID: 20617376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective comparison of hybrid capture 2 and SPF₁₀-LiPA for carcinogenic human papillomavirus detection and risk prediction of cervical cancer: a population-based cohort study in China.
    Dong L; Feng RM; Zhang L; Xu XQ; Zhao XL; Wang MZ; Qiao YL; Zhao FH
    J Gynecol Oncol; 2017 Sep; 28(5):e66. PubMed ID: 28657227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validation of a Human Papillomavirus (HPV) DNA Cervical Screening Test That Provides Expanded HPV Typing.
    Demarco M; Carter-Pokras O; Hyun N; Castle PE; He X; Dallal CM; Chen J; Gage JC; Befano B; Fetterman B; Lorey T; Poitras N; Raine-Bennett TR; Wentzensen N; Schiffman M
    J Clin Microbiol; 2018 May; 56(5):. PubMed ID: 29491018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Evaluation of cobas 4800 high-risk HPV test as a tool in cervical cancer screening and cytology triage].
    Chen W; Yu LL; Wang H; Fu CJ; Chen F; Cao YQ; Kang LN; Zhang X; Zhao FH; Geng L; Yu L
    Zhonghua Zhong Liu Za Zhi; 2012 Jul; 34(7):543-8. PubMed ID: 22967475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study.
    Monsonego J; Hudgens MG; Zerat L; Zerat JC; Syrjänen K; Halfon P; Ruiz F; Smith JS
    Int J Cancer; 2011 Aug; 129(3):691-701. PubMed ID: 20941740
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The PapilloCheck Assay for Detection of High-Grade Cervical Intraepithelial Neoplasia.
    Crosbie EJ; Bailey A; Sargent A; Gilham C; Peto J; Kitchener HC
    J Clin Microbiol; 2015 Nov; 53(11):3553-9. PubMed ID: 26338859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Budget impact analysis of cervical cancer screening in Portugal: comparison of cytology and primary HPV screening strategies.
    Pista A; Costa C; Saldanha C; Moutinho JAF; Moutinho JM; Arrobas F; Catalão C; Kempers J
    BMC Public Health; 2019 Feb; 19(1):235. PubMed ID: 30808324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alinity m HR HPV Assay Fulfills Criteria for Human Papillomavirus Test Requirements in Cervical Cancer Screening Settings.
    Oštrbenk Valenčak A; Šterbenc A; Seme K; Poljak M
    J Clin Microbiol; 2019 Dec; 58(1):. PubMed ID: 31666369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Machine Learning Interpretation of Extended Human Papillomavirus Genotyping by Onclarity in an Asian Cervical Cancer Screening Population.
    Wong OGW; Ng IFY; Tsun OKL; Pang HH; Ip PPC; Cheung ANY
    J Clin Microbiol; 2019 Dec; 57(12):. PubMed ID: 31511337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immediate histopathologic follow-up of cervista and aptima high-risk HPV assays in women with LSIL cytology.
    Zhang H; Varma KR; Han M; Matsko J; Zhao C
    Cancer Cytopathol; 2018 Aug; 126(8):525-532. PubMed ID: 29797678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative evaluation of three commercial systems for detection of high-risk human papillomavirus in cervical and vaginal ThinPrep PreservCyt samples and correlation with biopsy results.
    Binnicker MJ; Pritt BS; Duresko BJ; Espy MJ; Grys TE; Zarka MA; Kerr SE; Henry MR
    J Clin Microbiol; 2014 Oct; 52(10):3763-8. PubMed ID: 25122861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial.
    Cook DA; Mei W; Smith LW; van Niekerk DJ; Ceballos K; Franco EL; Coldman AJ; Ogilvie GS; Krajden M
    BMC Cancer; 2015 Dec; 15():968. PubMed ID: 26674353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A modified Latent Class Model assessment of human papillomavirus-based screening tests for cervical lesions in women with atypical glandular cells: a Gynecologic Oncology Group study.
    Carter RL; Kang L; Darcy KM; Kauderer J; Liao SY; Rodgers WH; Walker JL; Lankes HA; Dunn ST; Stanbridge EJ
    Cancer Causes Control; 2012 Dec; 23(12):2013-21. PubMed ID: 23073789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the hybrid capture II assay with the human papillomavirus DNA chip test for the detection of high-grade cervical lesions.
    Kang WD; Kim CH; Cho MK; Kim JW; Kim YH; Choi HS; Kim SM
    Int J Gynecol Cancer; 2009 Jul; 19(5):924-8. PubMed ID: 19574786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of clinical performances among Roche Cobas HPV, RFMP HPV PapilloTyper and Hybrid Capture 2 assays for detection of high-risk types of human papillomavirus.
    Yu S; Kwon MJ; Lee EH; Park H; Woo HY
    J Med Virol; 2015 Sep; 87(9):1587-93. PubMed ID: 25914215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.